Company intelligence
MediBeacon Inc.
Focused on fluorescent tracer-agent based systems to help provide vital and actionable measurement of organ function.
About MediBeacon Inc.
MediBeacon is a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection. MediBeacon’s use of proprietary fluorescent tracer agents coupled with transdermal detection technology focuses on providing vital and actionable measurement of organ function. MediBeacon owns over 55 granted U.S. patents and over 215 granted patents worldwide that provide extensive coverage of the MediBeacon® TGFR, including Lumitrace® injection, the sensor and algorithms, as well as other strategic uses of its proprietary pyrazine platform and sensor technology. The TGFR is approved for human use. Potential technology applications in gastroenterology, ophthalmology and surgery are in various stages of clinical development. MediBeacon is based in St. Louis, Missouri, with additional operations in Mannheim, Germany.
Verified activity
Signals from MediBeacon Inc.
3 published signals
Research & Knowledge
MediBeacon Inc. is featured in a clinical research project by Dr. Lui Forni, a lead intensive care medicine physician at the Royal Surrey County Hospital NHS Foundation Trust, who is looking forward to including transdermal GFR in future clinical research.
Reported by MediBeacon Inc.
Legal & Regulatory
MediBeacon Inc. received FDA approval for the TGFR System and is currently undergoing commercial launch in China.
Reported by MediBeacon Inc.
Presence & Recognition
MediBeacon Inc. was named one of the Top 5 Private Medical Device Companies to Watch by MD+DI.
Reported by MediBeacon Inc.